Show notes
Boston remains biotech's most influential hub, but the questions facing the region are increasingly global. Recorded live at Fierce Biotech Week in Boston, this panel discussion brings together Uli Stilz, senior advisor at Flagship Pioneering; Bruce Beutel, CEO and co-founder of PassKey; and Ben Bradford, head of external affairs at MassBio, for a conversation about the future of biotech innovation.
Highlighted moments
What I actually have seen in China is that they build actually the architecture of an ecosystem where there is a possibility to go very fast from a scientific insight into an early human clinical signal and then build a much faster iteration loop. So it's actually the innovation architecture, China's building, I think will be the key competitive threat.
“80% of them said their first preference of where to do first in human trials would be the U.S. But under the current market conditions, U.S. dropped to about 30%.”
“if we all focus on only validation, the result of this will at the end be an ecosystem which becomes more and more incremental.”
“most likely not the winners are the companies who have an asset, but actually those companies who built a learning system. And out of this learning system, it becomes repeatable to create new insights.”
Transcript
Transcript not available for this episode yet.
More from The Top Line
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 202611 min
Why modern clinical trials need a finance-first strategy (Sponsored)
Jul 20, 202617 min
5 emerging biotech hubs
Jul 17, 202624 min
Decision readiness is the next AI advantage (Sponsored)
Jul 13, 202618 min
A $10B deal, China trial scrutiny and highlights from ADA 2026
Jul 10, 202624 min